Cargando…

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma

Detalles Bibliográficos
Autores principales:	Franchini, Massimo, Baldanti, Fausto, Percivalle, Elena, Ferrari, Alessandro, Biasi, Pietro, Liumbruno, Giancarlo Maria, Glingani, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320387/ https://www.ncbi.nlm.nih.gov/pubmed/34391625 http://dx.doi.org/10.1016/j.tracli.2021.07.006

Ejemplares similares

The Three Pillars of COVID-19 Convalescent Plasma Therapy
por: Franchini, Massimo, et al.
Publicado: (2021)

Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent Plasma for the Treatment of Severe COVID-19
por: Franchini, Massimo, et al.
Publicado: (2021)

Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations
por: Franchini, M., et al.
Publicado: (2022)

Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients
por: Franchini, Massimo, et al.
Publicado: (2022)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
por: Focosi, D., et al.
Publicado: (2021)

Assessment of the impact of pathogen reduction technologies on the neutralizing activity of COVID-19 convalescent plasma.
por: Hindawi, Salwa, et al.
Publicado: (2023)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

Solvent/detergent plasma: pharmaceutical characteristics and clinical experience
por: Liumbruno, Giancarlo Maria, et al.
Publicado: (2014)

Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review
por: Franchini, Massimo, et al.
Publicado: (2021)

Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial
por: Perotti, Cesare, et al.
Publicado: (2020)

Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
por: Gontu, Abhinay, et al.
Publicado: (2021)

Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer
por: Bloch, Evan M, et al.
Publicado: (2021)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Effect of time and titer in convalescent plasma therapy for COVID-19
por: de Candia, Paola, et al.
Publicado: (2021)

Convalescent plasma for coronavirus disease 2019 in pregnancy: a case report and review
por: Grisolia, Gianpaolo, et al.
Publicado: (2020)

The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
por: Kroemer, Marie, et al.
Publicado: (2022)

Preservation of neutralizing antibody function in COVID‐19 convalescent plasma treated using a riboflavin and ultraviolet light‐based pathogen reduction technology
por: Yonemura, Susan, et al.
Publicado: (2021)

Loss of repeat convalescent plasma donors due to waning anti-SARS-CoV-2 plaque reduction neutralization test titers (April-December 2020)
por: Drews, Steven, et al.
Publicado: (2022)

Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology
por: Cognasse, Fabrice, et al.
Publicado: (2022)

The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2
por: Fisher, David L., et al.
Publicado: (2021)

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma
por: Salazar, Eric, et al.
Publicado: (2020)

Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma
por: Nguyen, Dung, et al.
Publicado: (2021)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol
por: Perotti, Cesare, et al.
Publicado: (2020)

Why should we use convalescent plasma for COVID-19?
por: Franchini, Massimo
Publicado: (2020)

Assessment of SARS-CoV-2 neutralizing antibody titers in breastmilk from convalescent and vaccinated mothers
por: Bäuerl, Christine, et al.
Publicado: (2023)

Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19
por: Fazeli, Alieh, et al.
Publicado: (2022)

Early administration of COVID‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy
por: Belov, Artur, et al.
Publicado: (2022)

The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors
por: Nurmi, Visa, et al.
Publicado: (2023)

Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial
por: Franchini, Massimo, et al.
Publicado: (2021)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
por: Focosi, Daniele, et al.
Publicado: (2022)

The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study
por: Nontawong, Nuttakant, et al.
Publicado: (2022)

The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors
por: Wardhani, Shinta Oktya, et al.
Publicado: (2021)

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
por: Sullivan, David J., et al.
Publicado: (2021)

Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h8bcsiblumes7fjf2i4dn3c9q9